[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334472-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334472-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microsatellite-instability-is-insufficiently-used-as-a-biomarker-for-lynch-syndrome-testing-in-clinical-practice","Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice","","Microsatellite instability (MSI)–positive tumors show clinical usefulness as an agnostic biomarker to identify patients eligible for immunotherapy. MSI is also a hallmark of Lynch syndrome (LS), the most common hereditary cancer susceptibility in colorectal and endometrial cancers. Despite international recommendations, MSI-high results are often ignored in practice, so LS-directed germline testing is frequently not pursued. This study assesses MSI prevalence and testing behaviors in a large Greek clinical cohort.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microsatellite-instability-is-insufficiently-used-as-a-biomarker-for-lynch-syndrome-testing-in-clinical-practice/334472/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microsatellite-instability-is-insufficiently-used-as-a-biomarker-for-lynch-syndrome-testing-in-clinical-practice/334472.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical value does microsatellite instability (MSI) testing provide?","Question",{"text":63,"@type":64},"MSI-positive tumors can guide immunotherapy eligibility and help identify patients who may carry germline cancer-predisposing variants linked to Lynch syndrome.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was MSI analysis performed and what follow-up tests were used?",{"text":68,"@type":64},"The study used an NGS-based technique for MSI analysis in 4,553 patients, with additional somatic BRAF analysis and hereditary cancer-associated gene testing for MSI-high cases. MLH1 promoter methylation was also assessed retrospectively in colorectal and endometrial cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the study’s key findings about MSI-high testing for Lynch syndrome?",{"text":72,"@type":64},"Overall MSI positivity was 5.27%. Among MSI-high cases, 45 patients (22.73%) underwent germline testing, and 24.44% of those had pathogenic LS-associated variants, while a majority did not receive LS genetic testing despite guidelines.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334472,1790176613,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Original Reports | Precision Medicine  \nMicrosatellite Instability Is Insufﬁciently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice  \nEirini Papadopoulou, PhD1 ; George Rigas, MD2; Elena Fountzilas, MD, PhD3 ; Anastasios Boutis, MD, PhD4; Stylianos Giassas, MD5; Nikolaos Mitsimponas, MD, MSc6; Danai Daliani, MD7 ; Dimitrios C Ziogas, MD8; Michalis Liontos, MD, PhD9 ; Vasileios Ramﬁdis, MD, MSc10; Charalampos Christophilakis, MD11; Dimitris Matthaios, MD, PhD12; Theofanis Floros, MD13; Chrysiida Florou-Chatzigiannidou, MSc1;  \nKonstantinos Agiannitopoulos, MSc, PhD1; Angeliki Meintani, MSc1; Aikaterini Tsantikidi, MSc1; Anastasia Katseli, PhD1 ; Kevisa Potska, MSc1; Georgios Tsaousis, MSc, PhD1 ; Vasiliki Metaxa-Mariatou, MSc1; and George Nasioulas, PhD1  \nDOI [https://doi.org/10.1200/PO.23.00332](https://doi.org/10.1200/PO.23.00332)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | The pan-cancer presence of microsatellite instability (MSI)–positive tumors demonstrates its clinical utility as an agnostic biomarker for identifying immunotherapy-eligible patients. Additionally, MSI is a hallmark of Lynch syndrome (LS), the most prevalent cancer susceptibility syndrome among patients with colorectal and endometrial cancer. Therefore, MSI-high results should inform germline genetic testing for cancer-predisposing genes. However, in clinical practice, such analysis is frequently disregarded. |\n| METHODS | A next-generation sequencing (NGS)–based technique was used for MSI analysis in 4,553 patients with various tumor types. Upon request, somatic BRAF gene analysis was conducted. In addition, hereditary testing of cancerassociated genes was performed in MSI-high cases using a capture-based NGS protocol. MLH1 promoter methylation analysis was conducted retrospectively in patients with colorectal and endometrial cancer to further investigate the origin of MSI at the tumor level. |\n| RESULTS | The MSI positivity rate for the entire cohort was 5.27% . Endometrial, gastric, colorectal, urinary tract, and prostate cancers showed the highest proportion of MSI-high cases (15.69%, 8.54%, 7.40%, 4.55%, and 3.19%, respectively) . A minority of 45 patients (22.73%) among the MSI-high cases underwent germline testing to determine whether the mismatch repair pathway deﬁciency was inherited. 24.44% of those who performed the genetic test carried a pathogenic variant in an LS-associated gene. Three MSI-high individuals had non-LS gene alterations, including BRCA1 , BRCA2 , and CDKN2A pathogenic variants, indicating the presence of non–LS-associated gene alterations among MSI-high patients. |\n| CONCLUSION | Although MSI analysis is routinely performed in clinical practice, as many as 77% of MSI-high patients do not undergo LS genetic testing, despite international guidelines strongly recommending it. BRAF andMLH1 methylation analysis could shed light on the somatic origin of MSI in 42.50% of the MSI-high patients; however, MLH1 analysis is barely ever requested in clinical practice. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted November 15, 2023 Published January 25, 2024  \nJCO Precis Oncol 8:e2300332 © 2024 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nThe mismatch repair pathway (MMR) is one of the primary DNA repair mechanisms, responsible for maintaining genomic stability and correcting DNA mismatches. MMRdeﬁcient cells are susceptible to mismatch errors during replication in the microsatellite regions.1 Tumors exhibiting microsatellite instability (MSI) are characterized as MSI-high. The MSI-high phenotype has been observed ina wide variety of tumor types, with higher prevalence in  \ncolorectal cancer (CRC) and endometrial carcinoma (EC) .2 ,3  \nLynch syndrome (LS), the most prevalent inherited CRC syndrome, with an autosomal dominant inheritance pattern, has been linked to MMR deﬁciency and occurs in 3% of patients with CRC and 6% of pat","cbCaig4OjXkiTHe6","https://ap.wps.com/l/cbCaig4OjXkiTHe6","pdf",724358,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context","[{\"question\":\"What clinical value does microsatellite instability (MSI) testing provide?\",\"answer\":\"MSI-positive tumors can guide immunotherapy eligibility and help identify patients who may carry germline cancer-predisposing variants linked to Lynch syndrome.\"},{\"question\":\"How was MSI analysis performed and what follow-up tests were used?\",\"answer\":\"The study used an NGS-based technique for MSI analysis in 4,553 patients, with additional somatic BRAF analysis and hereditary cancer-associated gene testing for MSI-high cases. MLH1 promoter methylation was also assessed retrospectively in colorectal and endometrial cancers.\"},{\"question\":\"What were the study’s key findings about MSI-high testing for Lynch syndrome?\",\"answer\":\"Overall MSI positivity was 5.27%. Among MSI-high cases, 45 patients (22.73%) underwent germline testing, and 24.44% of those had pathogenic LS-associated variants, while a majority did not receive LS genetic testing despite guidelines.\"}]","Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice | PDF",1790006792]